A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis in Subjects With Neovascular Age-related Macular Degeneration
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Samsung Bioepis
- 02 Jan 2019 Planned End Date changed from 1 Jul 2020 to 28 Nov 2019.
- 02 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 24 Jan 2019.
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.